We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+40.5%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$47M
AUM Growth
-$538M
(-92%)
Cap. Flow
-$549M
Cap. Flow
% of AUM
-1,168.39%
Top 10 Holdings %
Top 10 Hldgs %
25.17%
Holding
313
New
6
Increased
35
Reduced
92
Closed
155
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Franklin FTSE India ETF
FLIN
|
+$334K |
| 2 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$332K |
| 3 |
Enanta Pharmaceuticals
ENTA
|
+$224K |
| 4 |
Puma Biotechnology
PBYI
|
+$217K |
| 5 |
ARRY
Array Biopharma Inc
ARRY
|
+$217K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MPLX
MPLX
|
+$60.3M |
| 2 |
EQM
EQM Midstream Partners, LP
EQM
|
+$58.3M |
| 3 |
Energy Transfer Partners
ET
|
+$49.7M |
| 4 |
Enterprise Products Partners
EPD
|
+$41.7M |
| 5 |
MMP
Magellan Midstream Partners, L.P.
MMP
|
+$30.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.12% |
| 2 | Financials | 0.73% |
| 3 | Communication Services | 0.52% |
| 4 | Consumer Discretionary | 0.46% |
| 5 | Materials | 0.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TCDA
51
DELISTED
Tricida, Inc. Common Stock
TCDA
| $333K | 0.71% |
8,627
-1,006
| -10% | -$23.4K |
|
|
CBIO
52
Crescent Biopharma
CBIO
$602M
| $331K | 0.7% |
266
-33
| -11% | -$37.8K |
|
|
ASRT
53
DELISTED
Assertio
ASRT
| $326K | 0.69% |
1,072
-156
| -13% | -$40.2K |
|
54
Kura Oncology
KURA
$922M
| $323K | 0.69% |
19,441
-2,529
| -12% | -$39K |
|
|
AGEN
55
Agenus
AGEN
$249M
| $319K | 0.68% |
5,476
-679
| -11% | -$42.1K |
|
|
KDMN
56
DELISTED
Kadmon Holdings, Inc.
KDMN
| $317K | 0.67% |
119,987
-17,714
| -13% | -$44.7K |
|
57
Rocket Pharmaceuticals
RCKT
$348M
| $312K | 0.66% |
17,799
-1,805
| -9% | -$28.5K |
|
|
PRNB
58
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
| $308K | 0.66% |
9,048
-1,260
| -12% | -$40.1K |
|
59
Denali Therapeutics
DNLI
$3.67B
| $307K | 0.65% |
13,201
-1,589
| -11% | -$33.2K |
|
60
PTC Therapeutics
PTCT
$6.37B
| $299K | 0.64% |
7,947
-701
| -8% | -$23.5K |
|
61
Fate Therapeutics
FATE
$281M
| $292K | 0.62% |
16,612
-1,728
| -9% | -$27.3K |
|
62
Viking Therapeutics
VKTX
$4.04B
| $287K | 0.61% |
28,854
-3,457
| -11% | -$28.9K |
|
63
Corbus Pharmaceuticals
CRBP
$170M
| $282K | 0.6% |
1,354
-184
| -12% | -$40.6K |
|
|
APLS
64
DELISTED
Apellis Pharmaceuticals
APLS
| $280K | 0.6% |
14,338
-1,568
| -10% | -$24.7K |
|
65
Prothena Corp
PRTA
$458M
| $278K | 0.59% |
22,918
-2,964
| -11% | -$37K |
|
66
Akebia Therapeutics
AKBA
$327M
| $274K | 0.58% |
33,514
-4,669
| -12% | -$32K |
|
67
Cytokinetics
CYTK
$11B
| $273K | 0.58% |
33,758
-3,729
| -10% | -$27.4K |
|
|
XLRN
68
DELISTED
Acceleron Pharma
XLRN
| $271K | 0.58% |
5,810
-875
| -13% | -$38.4K |
|
|
ONC
69
BeOne Medicines Ltd
ONC
$33.8B
| $269K | 0.57% |
2,041
-209
| -9% | -$28.2K |
|
|
AIMT
70
DELISTED
Aimmune Therapeutics
AIMT
| $268K | 0.57% |
11,993
-1,694
| -12% | -$39.9K |
|
|
AUTL
71
Autolus Therapeutics
AUTL
$386M
| $265K | 0.56% |
8,434
-1,068
| -11% | -$30.4K |
|
|
ATNX
72
DELISTED
Athenex, Inc. Common Stock
ATNX
| $263K | 0.56% |
1,073
-152
| -12% | -$37.1K |
|
73
Marker Therapeutics
MRKR
$20.3M
| $262K | 0.56% |
3,967
-529
| -12% | -$30.9K |
|
74
Abeona Therapeutics
ABEO
$345M
| $261K | 0.56% |
1,419
-182
| -11% | -$32.5K |
|
75
Rhythm Pharmaceuticals
RYTM
$7B
| $260K | 0.55% |
9,468
-1,044
| -10% | -$30K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q1 2019 Portfolio in Review
As of Q1 2019, Virtus ETF Advisers held 313 positions worth $47M, down 92% from $585M the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Virtus ETF Advisers withdrew a net $549M in Q1 2019, closing 155 positions and reducing 92 holdings. Its most notable exit was MPLX, an estimated $60.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 7.3% a quarter earlier, followed by Financials and Communication Services.
Against the trend, Virtus ETF Advisers opened a new position in Meta Platforms (Facebook) worth $73K.
- Virtus ETF Advisers's largest Q1 2019 buy was Meta Platforms (Facebook): 435 shares worth $73K.
- Virtus ETF Advisers added most to Franklin FTSE India ETF in Q1 2019, an estimated $334K increase.
- Virtus ETF Advisers's biggest Q1 2019 reduction was Marathon Petroleum, cutting an estimated $21.6M.
- Virtus ETF Advisers fully exited MPLX in Q1 2019, selling an estimated $60.3M.
- Virtus ETF Advisers's ten largest holdings make up 25% of its $47M portfolio in Q1 2019.
- Virtus ETF Advisers opened 6 new positions and closed 155 in Q1 2019.
- Virtus ETF Advisers's portfolio value fell 92% quarter-over-quarter to $47M.
Based on Virtus ETF Advisers's 13F filing for Q1 2019, filed 14 May 2019.